ArticleInternational journal of chronic obstructive pulmonary disease2026
The Role of Advanced Lung Cancer Inflammation Index in Predicting COPD Exacerbation Risks.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The role of the Advanced Lung Cancer Inflammation Index (ALI) in chronic obstructive pulmonary disease (COPD) remains unclear, although it has been utilized to investigate various non-malignant conditions. Methods: A prospective study involving Chinese patients with COPD was carried out in Hong Kong to examine the relationship between baseline ALI levels and the risk of acute exacerbations of COPD (AECOPD). ALI was evaluated across quartiles. Patients were prospectively recruited from respiratory clinic in Queen Mary Hospital and Grantham Hospital in 2021, follow up with patients was done until 8th March 2025 or the death date, whichever is earlier. Results: Among 272 Chinese COPD patients recruited, 138 of them had moderate to severe AECOPD and 66 patients died in the follow-up period. Those in the Q1 ALI, when compared with Q4 (highest quartile), had significantly shorter time to moderate to severe AECOPD with adjusted hazard ratio of (aHR) 2.17 (95% CI = 1.29-3.65, p = 0.011), severe AECOPD (aHR 2.05, 95% CI = 1.18-3.55, p = 0.011) and overall survival (aHR 2.73, 95% CI = 1.21-6.15, p = 0.015). The same phenomenon was also observed in the patient subgroup with baseline blood eosinophil counts <300 cells/μL. Conclusion: In this prospective study, it suggested that ALI can serve as a biomarker to predict the risk of moderate to severe AECOPD, as well as severe AECOPD and mortality. The phenomenon was also observed in the non-eosinophilic subgroup. This can allow clinicians to use this simple and repeatable biomarker as a way to prognosticate COPD patients and estimate AECOPD risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.